Jaeger C, Allendörfer J, Hatziagelaki E, Dyrberg T, Bergis K H, Federlin K, Bretzel R G
Third Medical Department and Policlinic, Justus Liebig University, Giessen, Germany.
Horm Metab Res. 1997 Oct;29(10):510-5. doi: 10.1055/s-2007-979091.
Persistent humoral autoimmunity to the enzyme glutamic acid decarboxylase (GAD) has been described in a substantial proportion of patients with insulin-dependent diabetes mellitus (IDDM) of long duration. The source of the stimulus for this autoimmune reactivity is still unknown. Because the GAD 65 isoform is mainly expressed in pancreatic beta-cells and in the nervous system we investigated in the present study of the largest number of well characterized patients with longstanding IDDM (n = 105; median duration: 21 years; range: 10-46 years) the presence of autoantibodies to GAD 65 and their relationship to a residual C-peptide response or peripheral and autonomic neuropathy. Additionally we studied the HLA-DR status relative to GAD 65 antibodies in 86 out of the 105 individuals. One hundred healthy control subjects and 100 recent onset IDDM patients were also studied for GAD 65 antibodies. GAD 65 antibodies were detected in a radioligand-binding-assay with recombinant human GAD 65 and were present in 32% of the long-term diabetic patients, 82% of the recent onset IDDM patients and in 3% of the healthy control subjects. A preserved C-peptide response to i.v. glucagon (Hendriksen criteria) was observed in 23% of the long-term IDDM patients. Autonomic neuropathy and peripheral neuropathy was identified using criteria based on both symptoms and formal testing giving a frequency of 67% vs 79%. The HLA specific DR 4/X was observed in 47% and HLA-DR 3/X in 22% of the long-term IDDM patients. Patients who were heterozygous for DR3/DR4 were found in 23% of the cases. GAD 65 antibodies were significantly less frequent in the long-term IDDM patients compared to recent onset IDDM (p < 0.001), and diabetes duration showed a significant negative correlation with GAD 65 antibody index levels (r = 0.22, p < 0.01). Interestingly, GAD 65 antibodies were not significantly correlated either with residual beta-cell function or neuropathy and no particular HLA-DR status was associated with persistent GAD 65 antibodies. In conclusion neither residual beta-cell function nor diabetic neuropathy or a certain HLA-DR specificity are exclusively associated with persistent autoimmunity directed to GAD 65 in longstanding IDDM. The stimulus for the persistent humoral immune response and its significance for the disease process and its complications remain to be established.
在相当一部分病程较长的胰岛素依赖型糖尿病(IDDM)患者中,已发现存在针对谷氨酸脱羧酶(GAD)的持续性体液自身免疫反应。这种自身免疫反应性刺激的来源尚不清楚。由于GAD 65同工型主要在胰腺β细胞和神经系统中表达,因此在本研究中,我们对数量最多的、特征明确的长期IDDM患者(n = 105;中位病程:21年;范围:10 - 46年)进行了研究,检测其抗GAD 65自身抗体的存在情况,以及这些抗体与残余C肽反应或周围神经病变和自主神经病变的关系。此外,我们还在105名患者中的86名患者中研究了与GAD 65抗体相关的HLA - DR状态。还对100名健康对照者和100名新发病的IDDM患者进行了GAD 65抗体检测。采用重组人GAD 65进行放射性配体结合测定,结果显示,32%的长期糖尿病患者、82%的新发病IDDM患者以及3%的健康对照者体内存在GAD 65抗体。23%的长期IDDM患者对静脉注射胰高血糖素(亨德里克森标准)有保留的C肽反应。根据症状和正式检测标准确定自主神经病变和周围神经病变,其发生率分别为67%和79%。长期IDDM患者中,47%观察到HLA特异性DR 4/X,22%观察到HLA - DR 3/X。23%的病例中发现DR3/DR4杂合子患者。与新发病的IDDM患者相比,长期IDDM患者中GAD 65抗体的出现频率显著降低(p < 0.001),糖尿病病程与GAD 65抗体指数水平呈显著负相关(r = 0.22,p < 0.01)。有趣的是,GAD 65抗体与残余β细胞功能或神经病变均无显著相关性,且没有特定的HLA - DR状态与持续性GAD 65抗体相关。总之,在长期IDDM中,残余β细胞功能、糖尿病神经病变或特定的HLA - DR特异性均与针对GAD 65的持续性自身免疫反应无排他性关联。持续性体液免疫反应的刺激因素及其对疾病进程及其并发症的意义仍有待确定。